GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (CHIX:0QFd) » Definitions » Investments And Advances

Moderna (CHIX:0QFD) Investments And Advances : €2,190 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Moderna Investments And Advances?

Moderna's Investments And Advances for the quarter that ended in Jun. 2024 was €2,190 Mil.

Moderna's quarterly Investments And Advances declined from Dec. 2023 (€4,349 Mil) to Mar. 2024 (€3,396 Mil) and declined from Mar. 2024 (€3,396 Mil) to Jun. 2024 (€2,190 Mil).

Moderna's annual Investments And Advances increased from Dec. 2021 (€6,056 Mil) to Dec. 2022 (€7,892 Mil) but then declined from Dec. 2022 (€7,892 Mil) to Dec. 2023 (€4,349 Mil).


Moderna Investments And Advances Historical Data

The historical data trend for Moderna's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Investments And Advances Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial 143.99 525.26 6,056.06 7,891.84 4,349.33

Moderna Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,744.75 5,021.38 4,349.33 3,395.72 2,189.65

Moderna Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Moderna Business Description

Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna Headlines

No Headlines